$DYAI
Dyadic International Inc Stock $dyai

$dyai Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000143774923008425 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$978.1K	$743.7K	$2.930M
YoY Change	-99.85%	137.39%	21.9%
Cost Of Revenue	$726.9K	$704.5K	$2.123M
YoY Change	-99.82%	112.43%	9.19%
Gross Profit	$251.1K	$39.24K	$807.1K
YoY Change	-99.9%	-313.96%	75.69%
Gross Profit Margin	25.68%	5.28%	27.54%
Selling, General & Admin	$1.480M	$1.668M	$6.422M
YoY Change	-10.61%	-2.04%	-4.12%
% of Gross Profit	589.34%	4251.63%	795.62%
Research & Development	$810.6K	$584.1K	$4.501M
YoY Change	-99.94%	-76.38%	-46.36%
% of Gross Profit	322.76%	1488.58%	557.71%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$810.6K	$2.252M	$4.501M
YoY Change	-99.94%	-46.07%	-46.36%
Operating Profit	-$2.050M	-$2.213M	-$10.17M
YoY Change	-99.93%	-47.24%	-30.97%
Interest Expense	$104.7K	$316.8K	$180.4K
YoY Change	-96.47%	-80.03%	248.95%
% of Operating Profit
Other Income/Expense, Net	$1.094M	-$250.0K	$430.4K
YoY Change	-99.57%	-84.43%	-74.03%
Pretax Income	-$956.4K	-$2.146M	-$9.828M
YoY Change	-61.61%	-49.06%	-25.06%
Income Tax
% Of Pretax Income
Net Earnings	-$956.4K	-$2.146M	-$9.735M
YoY Change	-61.61%	-49.06%	-25.52%
Net Earnings / Revenue	-97.79%	-288.6%	-332.23%
Basic Earnings Per Share	-$0.03		-$0.34
Diluted Earnings Per Share	-$0.03	-$0.08	-$0.34
COMMON SHARES
Basic Shares Outstanding	28.81M	28.56M	28.36M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.74M	$12.64M	$12.64M
YoY Change	-23.99%	-37.6%	-37.6%
Cash & Equivalents	$6.374M	$5.794M	$5.794M
Short-Term Investments	$5.363M	$6.847M	$6.847M
Other Short-Term Assets	$284.6K	$392.2K	$392.2K
YoY Change	16.56%	4.37%	4.37%
Inventory
Prepaid Expenses
Receivables	$754.1K	$330.0K	$330.0K
Other Receivables	$30.08K	$58.29K	$58.29K
Total Short-Term Assets	$12.81M	$13.42M	$13.42M
YoY Change	-99.92%	-36.11%	-36.11%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$284.7K	$284.7K
YoY Change	-100.0%	0.0%	0.0%
Other Assets	$6.065K	$6.045K	$6.050K
YoY Change	-99.9%	-1.18%	-1.14%
Total Long-Term Assets	$6.065K	$290.8K	$290.8K
YoY Change	-100.0%	-0.02%	-0.02%
TOTAL ASSETS
Total Short-Term Assets	$12.81M	$13.42M	$13.42M
Total Long-Term Assets	$6.065K	$290.8K	$290.8K
Total Assets	$12.81M	$13.71M	$13.71M
YoY Change	-99.93%	-35.62%	-35.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$770.4K	$1.276M
YoY Change	-99.91%	-17.55%
Accrued Expenses	$863.0K	$955.1K	$955.1K
YoY Change	-99.84%	34.6%	34.6%
Deferred Revenue	$65.21K	$40.74K
YoY Change	-99.98%	-73.04%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.875M	$2.449M	$2.449M
YoY Change	-99.9%	-4.19%	-4.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$132.4K	$176.5K	$176.5K
YoY Change	-57.14%	-50.0%	-50.0%
Total Long-Term Liabilities	$132.4K	$176.5K	$176.5K
YoY Change	-57.14%	-50.0%	-50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.875M	$2.449M	$2.449M
Total Long-Term Liabilities	$132.4K	$176.5K	$176.5K
Total Liabilities	$2.007M	$2.625M	$2.625M
YoY Change	-99.91%	-9.75%	-9.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$74.44M	-$73.48M
YoY Change	-99.89%	15.27%
Common Stock	$41.07K	$40.82K
YoY Change	-99.9%	0.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$18.93M	$18.90M
YoY Change	-99.9%	-0.16%
Treasury Stock Shares
Shareholders Equity	$10.80M	$11.09M	$11.09M
YoY Change
Total Liabilities & Shareholders Equity	$12.81M	$13.71M	$13.71M
YoY Change	-99.93%	-35.62%	-35.62%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$956.4K	-$2.146M	-$9.735M
YoY Change	-61.61%	-49.06%	-25.52%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.187M	-$1.682M	-$8.084M
YoY Change	-99.92%	-36.18%	-28.32%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$2.767M	$617.9K	-$2.369M
YoY Change	-631.29%	-86.27%	-145.37%
Cash From Investing Activities	$2.767M	$617.9K	-$2.369M
YoY Change	-100.53%	-86.27%	-145.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	141.5K	$543.6K
YoY Change	-100.0%	-42.13%	-55.81%
NET CHANGE
Cash From Operating Activities	-$2.187M	-1.682M	-$8.084M
Cash From Investing Activities	$2.767M	617.9K	-$2.369M
Cash From Financing Activities	$0.00	141.5K	$543.6K
Net Change In Cash	$579.8K	-922.4K	-$9.954M
YoY Change	-100.02%	-143.73%	103.62%
FREE CASH FLOW
Cash From Operating Activities	-$2.187M	-$1.682M	-$8.084M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103458697	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101026496	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18929915	usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40816602
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40482659
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28563100
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28229157
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2022	dyai	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	0	usd
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1000000.0	eur
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M20D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M20D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M3D
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y25D
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18900000	usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55264
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0486747
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	140 Intracoastal Pointe Drive, Suite 404
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Jupiter
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33477
CY2022	dei	City Area Code CityAreaCode	561
CY2022	dei	Local Phone Number LocalPhoneNumber	743-8333
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	DYAI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	60900000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28811061
CY2022	dei	Auditor Firm AuditorFirmId	199
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2022	dei	Auditor Location AuditorLocation	St. Peterburg, Florida
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5794272	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15748480	usd
CY2022Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	6847270	usd
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	4511780	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	58285	usd
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	94375	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	330001	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	277831	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	392236	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	375830	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	13422064	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21008296	usd
CY2022Q4	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	284709	usd
CY2021Q4	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	284709	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6045	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6117	usd
CY2022Q4	us-gaap	Assets Assets	13712818	usd
CY2021Q4	us-gaap	Assets Assets	21299122	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1276313	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547953	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955081	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	709560	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	40743	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	151147	usd
CY2022Q4	dyai	Deferred License Revenue Current DeferredLicenseRevenueCurrent	176471	usd
CY2021Q4	dyai	Deferred License Revenue Current DeferredLicenseRevenueCurrent	147059	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2448608	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2555719	usd
CY2022Q4	dyai	Deferred License Revenue Net Of Current Portion DeferredLicenseRevenueNetOfCurrentPortion	176471	usd
CY2021Q4	dyai	Deferred License Revenue Net Of Current Portion DeferredLicenseRevenueNetOfCurrentPortion	352941	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2625079	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2908660	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40817	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	40483	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18929915	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73481860	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63746602	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11087739	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18390462	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13712818	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21299122	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2930303	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2403831	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2123193	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1944438	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4501365	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8392370	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6421505	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6697617	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-49918	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-96893	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	13095981	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	17131318	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10165678	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14727487	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	180420	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	51704	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	250000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1605532	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	430420	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1657236	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9735258	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13070251	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	28364482
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27838047
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28446561	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1784102	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1230050	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13070251	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18390462	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1888944	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	543591	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9735258	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11087739	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9735258	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-13070251	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1888944	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1784102	usd
CY2022	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	33790	usd
CY2021	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	329612	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-0	usd
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	1605532	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-49918	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-96893	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-36090	usd
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-17872	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	83265	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31792	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13925	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95366	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-248128	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	549562	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	245521	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	219824	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-147058	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	500000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-110404	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	28131	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8083775	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11276945	usd
CY2022	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	9869280	usd
CY2021	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	11283940	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	7500000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	14900000	usd
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	0	usd
CY2021	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	1605532	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2369280	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5221592	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	543591	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1230050	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	543591	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1230050	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-44744	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-63262	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9954208	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4888565	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15748480	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20637045	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5794272	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15748480	usd
CY2022	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	51045000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"/>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">For each of the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company’s revenue was generated from fourteen customers. As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company’s accounts receivable was from six and eight customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company had six and eight customers outside of the United Sates (i.e. European and Asian customers) that accounted for approximately $586,000 or 21.8% and $1,716,000 or 71.3% of total revenue, respectively. As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company had four and four customers outside of the United Sates (i.e. European and Asian customers) that accounted for approximately $91,000 or 27.4% and $157,000 or 56.4% of accounts receivable, respectively.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company uses several contract research organizations (“CROs”) to conduct its research projects and manage its clinical trial. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em>, three CROs accounted for approximately $5,575,000 or 97.9% and $9,061,000 or 95.1% of total research services we purchased, respectively. As of <em style="font: inherit;"> December 31, 2022</em>, three CROs accounted for approximately $1,018,000 or 79.7% of accounts payable. As of <em style="font: inherit;"> December 31, 2021</em>, two CROs accounted for approximately $1,312,000 or 84.8% of accounts payable. The loss of business from any CRO or a combination of the Company’s CROs could adversely affect its operations.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"/>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	330001	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	277831	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	265429	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	326712	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	124273	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	45839	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2534	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3279	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	392236	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	375830	usd
CY2022	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	3707269000	usd
CY2021	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	7607035000	usd
CY2022	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	743051000	usd
CY2021	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	773823000	usd
CY2022Q4	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	1067958	usd
CY2021Q4	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	1363889	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	56514	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	27675	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	151841	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	156389	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1276313	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547953	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	580264	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	405758	usd
CY2022Q4	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	343457	usd
CY2021Q4	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	194250	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31360	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	109552	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955081	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	709560	usd
CY2021	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	11512000	usd
CY2022	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	4501365000	usd
CY2021	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	8392370000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15748480	usd
CY2021Q4	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	20257765	usd
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	2495	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5031097
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4774215
CY2022Q4	us-gaap	Cash Cash	26782	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5767490	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5794272	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5794272	usd
CY2022Q4	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	12594334	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	47208	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	12641542	usd
CY2021Q4	us-gaap	Cash Cash	1377094	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	14371386	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	15748480	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1341900	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	947400	usd
CY2021Q4	us-gaap	Investments And Cash InvestmentsAndCash	20260260	usd
CY2021Q4	dyai	Upfront Payment Payable UpfrontPaymentPayable	500000	usd
CY2021Q4	dyai	Number Of Performance Obligations NumberOfPerformanceObligations	2	pure
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1100000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9828427	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13115869	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	93169	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	45618	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-9735258	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-13070251	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0435	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0452	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0084	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2477	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2809	pure
CY2022	dyai	Effective Income Tax Rate Reconciliation Trueup Adjustment Percent EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent	0.0034	pure
CY2021	dyai	Effective Income Tax Rate Reconciliation Trueup Adjustment Percent EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent	0.0006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0024	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0009	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0188	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11524900	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10509900	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1623100	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1656500	usd
CY2022Q4	dyai	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	1046400	usd
CY2021Q4	dyai	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	-0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	72100	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-78200	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-6100	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15458100	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13035600	usd
CY2022Q4	dyai	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	15458100	usd
CY2021Q4	dyai	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	13035600	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	44000000.0	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	39900000	usd
CY2022Q4	dyai	Operating Loss Carryforwards Will Be Carried Forward Indefinitely OperatingLossCarryforwardsWillBeCarriedForwardIndefinitely	41100000	usd
CY2021Q4	dyai	Operating Loss Carryforwards Will Be Carried Forward Indefinitely Available To Offset Taxable Income Percentage OperatingLossCarryforwardsWillBeCarriedForwardIndefinitelyAvailableToOffsetTaxableIncomePercentage	0.80	pure
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	2912761	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	164794	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	40951	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	3118506	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4638390
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.44
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13701610	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	870825
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.11
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	735000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4774215
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8413444	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	865825
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.43
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	333943
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	200000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.47
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	75000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.81
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5031097
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3655280
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.80
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.49
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	365000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1730000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	919000	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	857000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1888944	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1784102	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.63
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18900000	usd
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001

Files In Submission

Name	View Source	Status
dyai-20221231_cal.xml	Edgar Link	unprocessable
0001437749-23-008425-index-headers.html	Edgar Link	pending
0001437749-23-008425-index.html	Edgar Link	pending
0001437749-23-008425.txt	Edgar Link	pending
0001437749-23-008425-xbrl.zip	Edgar Link	pending
dyai-20221231.xsd	Edgar Link	pending
dyai20201008_10kimg001.jpg	Edgar Link	pending
dyai20221231_10k.htm	Edgar Link	pending
ex_449718.htm	Edgar Link	pending
ex_449720.htm	Edgar Link	pending
ex_449721.htm	Edgar Link	pending
ex_449722.htm	Edgar Link	pending
ex_449723.htm	Edgar Link	pending
ex_493857.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
dyai-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dyai-20221231_def.xml	Edgar Link	unprocessable
dyai-20221231_pre.xml	Edgar Link	unprocessable
dyai20221231_10k_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DYAI
Dyadic International Inc Stock $dyai

2023 Q1 Form 10-K Financial Statement

#000143774923008425 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI Dyadic International Inc Stock $dyai

2023 Q1 Form 10-K Financial Statement

#000143774923008425 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI
Dyadic International Inc Stock $dyai